micro-community-banner
 
  • Saved

3yr
The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice - PubMed

The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35427802/

the mTOR pathway was attenuated, and the insulin signaling and the AMPK pathway were enhanced by semaglutide, ameliorating the liver gene expressions related to the metabolism of obese mice. These...



Conclusion: - the mTOR pathway was attenuated, and the insulin signaling and the AMPK pathway were enhanced by semaglutide, ameliorating the liver gene expressions related to the metabolism of obese mice. These findings are promising in delaying the progression of nonalcoholic fatty liver disease.


  • 3yr
    glucagon-like peptide type 1 receptor agonist (GLP-1) is indicated to treat obesity-related liver metabolic alterations.
  • Saved

3yr
Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients - Journal of Endocrinological Investigation

Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients - Journal of Endocrinological Investigation

Source : https://link.springer.com/article/10.1007/s40618-022-01799-2

Purpose Registered trials and real-world evidence (RWE) studies provided evidence on the efficacy of once-weekly (OW) semaglutide on hyperglycaemia and cardiovascular risk factors as add-on or de-novo treatment in type...



Conclusions: Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.

  • Saved

3yr
Type 2 Diabetes

Over 34 million1 Americans have diabetes, and 90-95%2 of them have Type 2 Diabetes. When diet and lifestyle changes fail to improve glycemic control, metformin3 is typically the first treatment prescribed. Several novel drugs and classes have emerged to treat Type 2 Diabetes after or in addition to metformin. These include GLP-1 receptor agonists, DPP-4 and SGLT2 inhibitors.




  • What factors do you consider when adding to or switching from metformin?

  • What have been your experiences with some of the newer/novel Type 2 Diabetes drugs and classes?



 



References:




  1. National Diabetes Statistics Report, 2020

  2. CDC Diabetes Basics, accessed 11 Jan 2022

  3. Mayo Clinic Type 2 Diabetes Diagnosis and Treatment, accessed 11 Jan 2022


  • 3yr
    Incretin therapy is key as there is a relative deficiency or decreased responsiveness in metabolic syndrome and type 2 DM. With the GIP moiety being added to the GLP-1 Show More
  • 3yr
    Rybelsus ( it is oral Ozempic Semaglutide ) has come up as a block buster diabetic medicine in both managing diabetes and Obeisty , having phenomenal results that Show More

Show More Comments

  • Saved

3yr
Type 2 Diabetes

Over 34 million1 Americans have diabetes, and 90-95%2 of them have Type 2 Diabetes. When diet and lifestyle changes fail to improve glycemic control, metformin3 is typically the first treatment prescribed. Several novel drugs and classes have emerged to treat Type 2 Diabetes after or in addition to metformin. These include GLP-1 receptor agonists, DPP-4 and SGLT2 inhibitors.

  • What factors do you consider when adding to or switching from metformin?
  • What have been your experiences with some of the newer/novel Type 2 Diabetes drugs and classes?

 

References:

  1. National Diabetes Statistics Report, 2020
  2. CDC Diabetes Basics, accessed 11 Jan 2022
  3. Mayo Clinic Type 2 Diabetes Diagnosis and Treatment, accessed 11 Jan 2022
  • 3yr
    Incretin therapy is key as there is a relative deficiency or decreased responsiveness in metabolic syndrome and type 2 DM. With the GIP moiety being added to the GLP-1 Show More
  • 3yr
    Rybelsus ( it is oral Ozempic Semaglutide ) has come up as a block buster diabetic medicine in both managing diabetes and Obeisty , having phenomenal results that Show More

Show More Comments

  • Saved

3yr
Type 2 Diabetes

Over 34 million1 Americans have diabetes, and 90-95%2 of them have Type 2 Diabetes. When diet and lifestyle changes fail to improve glycemic control, metformin3 is typically the first treatment prescribed. Several novel drugs and classes have emerged to treat Type 2 Diabetes after or in addition to metformin. These include GLP-1 receptor agonists, DPP-4 and SGLT2 inhibitors.




  • What factors do you consider when adding to or switching from metformin?

  • What have been your experiences with some of the newer/novel Type 2 Diabetes drugs and classes?



 



References:




  1. National Diabetes Statistics Report, 2020

  2. CDC Diabetes Basics, accessed 11 Jan 2022

  3. Mayo Clinic Type 2 Diabetes Diagnosis and Treatment, accessed 11 Jan 2022


  • 3yr
    Incretin therapy is key as there is a relative deficiency or decreased responsiveness in metabolic syndrome and type 2 DM. With the GIP moiety being added to the GLP-1 Show More
  • 3yr
    Rybelsus ( it is oral Ozempic Semaglutide ) has come up as a block buster diabetic medicine in both managing diabetes and Obeisty , having phenomenal results that Show More

Show More Comments